Pfizer’s oral antiviral therapy, Paxlovid, may be associated with a higher incidence of COVID-rebound than previously believed, according to a new study published in the Annals of Internal Medicine. The study, which analyzed over 120 individuals, found that approximately 20% of those who received Paxlovid experienced an increase in viral levels after completing the five-day therapy. In comparison, only 2% of those who did not use the drug displayed a viral rebound.
This new finding contradicts previous data that had suggested Pfizer’s treatment was linked to only 1-2% of virological rebound. The study, which was funded by the National Institutes of Health (NIH) and conducted in a healthcare system in Boston, Massachusetts, acknowledges the limitations of its small sample size and the differences between the treated and untreated groups.
Despite the study’s findings, Pfizer has refused to comment on the results. However, the study authors recommend further trials to better understand the relationship between Paxlovid and virological rebound. This includes taking into account factors such as delayed treatment initiation and longer therapeutic courses.
Despite the potential concerns raised by the study, Pfizer maintains confidence in Paxlovid’s effectiveness in preventing severe outcomes from COVID-19 in high-risk patients. The drug has been authorized for emergency use by the U.S. Food and Drug Administration (FDA) and has shown promising results in reducing hospitalizations and deaths among high-risk individuals.
As the world continues to battle the ongoing pandemic, it is crucial to gather more data and conduct further research to ensure the safety and efficacy of antiviral therapies like Paxlovid. With the emergence of new variants and the need for effective treatments, understanding the potential risks and benefits of these medications is paramount in our fight against COVID-19.
“Infuriatingly humble tv expert. Friendly student. Travel fanatic. Bacon fan. Unable to type with boxing gloves on.”